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I.  INTRODUCTION 
 
In 2001, the United States invaded Afghanistan.
1
 Two years later, American armed 
forces were fully deployed in both Afghanistan and Iraq, and their presence persists to 
this day.
2
  Amidst the loss of life exists a subtler tragedy: psychiatrists report that 
around 20% of service members suffer from post-traumatic stress disorder upon 
returning home from combat.
3
  More distressingly, an average of 22 veterans commit 
suicide each day.
4
 
Though anecdotal, the story of Andrew Brennan provides an extreme but powerful 
narrative of PTSD’s suffocating grasp on returning veterans.5  The State of Alabama 
recently refused to stay the execution of the 66-year-old Vietnam veteran who was 
imprisoned for shooting an Atlanta police officer in 1998.
6
  At trial, Mr. Brennan’s 
lawyers pointed out that he had been diagnosed with severe posttraumatic stress 
disorder as a result of his service in Vietnam.
7
  On the night of the shooting, Mr. 
Brennan was “in the throes of an emotional flashback” when he pulled a rifle from his 
truck and began shooting at the officer.
8
  At the time of the tragedy, Mr. Brennan had 
been prescribed anti-psychotic medication for a diagnosed bipolar disorder.
9
 This 
approach—a reliance solely on prescription medication as a remedy for PTSD—
proved unsuccessful here, as it has so many times before.
10
 
Although many of organizations exist to support troops suffering with post-
traumatic stress disorder,
11
 a veteran’s ability to receive effective emerging treatments 
from their healthcare provider is frustrated by outdated legislation.
12
  Emerging 
                                                          
* Jonathan Perry J.D. Cleveland-Marshall College of Law, 2016. 
 1 BARBARA SALAZAR TORREON, CONGRESSIONAL REPORT SERVICE, U.S. PERIODS OF WAR 
(2010). 
 2  Id. 
 3 See Lisa Richardson et al., Prevalence Estimates of Combat-Related PTSD: A Critical 
Review, 44 AUSTRALIAN AND NEW ZEALAND J. OF PSYCHIATRY 4 (2011).  
 4 See JANET KEMP AND RONALD BOSSARTE, DEP’T OF VETERAN AFFAIRS, SUICIDE REPORT: 
2012 (2013). 
 5 Panel Refuses to Stop Execution of Vietnam Vet With PTSD, MIL. TIMES (January 13, 
2015). 
 6 Id. 
 7 Id. 
 8 Id. 
 9 Id.   
 10 See, e.g. Disjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of 
Chronic Military Service–Related PTSD, 306 J. of Am. Med. Ass’n 5 (2011). 
 11 Id. 
 12 See Justin Smith, The Values and Control of MDMA, 10 CONTEMP. JUSTICE REV. 297 
(2007). 
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treatments and research seeking to combat PTSD are hindered by the Drug 
Enforcement Agency’s (“DEA”) interpretation, and subsequent reinterpretations, of 
the Controlled Substances Act.
13
 Scheduling substances as “Schedule I” prohibits 
healthcare professionals from utilizing emerging remedies in PTSD treatment by 
erecting various administrative and bureaucratic barriers to research. 
14
 As a result, 
some substances with positive medical purposes are kept from those who must be 
afforded all possible remedies.
15
 
Schedule I classification requires medical researchers to obtain FDA approval 
before experimentation, a burdensome hurdle in the way of furthering understanding 
of the substance.
16
  Researchers are further required to record and secure all testing 
procedures in conformance with DEA guidelines, a process that further confines the 
scope of research.
17
  Lastly, classifying drugs as Schedule I has historically created a 
stigma that makes research vastly more difficult, as volunteers become scarce and the 
incentive to investigate becomes associated with criminal behavior and a poor 
professional reputation. 
18
  The timing of the classification strikes a massive blow to 
the mental stability of returning troops; neurological and psychopharmacological 
research began providing its most insightful and promising research just as the federal 
government began crippling access to the substance.  As a result, a massive pool of 
veterans, ranging from Vietnam to the current engagement, were stripped of a chance 
to alleviate the vicious symptoms of post-traumatic stress disorder. 
The most compelling emerging treatment is commonly referred to as “MDMA-
assisted psychotherapy,” in which psychiatrists incorporate 3,4-methylenedioxy-
methamphetamine into one-on-one or group therapy sessions with veterans suffering 
with PTSD.
19
  Although psychiatrists studied the therapeutic benefits of MDMA-
assisted psychotherapy throughout the 1970’s and 1980’s, research was suppressed by 
the DEA’s classification of MDMA as a Schedule I substance in 1986.20  In the last 
decade, however, there has been a resurgence of interest, funding, and medical 
                                                          
 13 Id. 
 14 Id. 
 15 See Alan Zarembo, Exploring Therapeutic Effects of MDMA on Post-Traumatic stress, 
L.A. TIMES, (March 15, 2014), http://articles.latimes.com/2014/mar/15/local/la-me-mdma-
20140316.  
 16 Grinspoon v. Drug Enforcement Admin., 828 F.2d 881, 896 (1st Cir. 1987).  “Dr. 
Grinspoon has correctly identified several ways in which the placement of MDMA in Schedule 
I will impede his research and the efforts of other researchers interested in exploring the 
possibility of clinical uses for MDMA.”  Id.   
 17 Id. 
 18 Renee Lewis, DEA approves study using MDMA for anxiety in seriously ill patients, Al 
Jazeera America (March 17, 2015),  http://america.aljazeera.com/articles/2015/3/17/clinical-
trial-approved-for-mdma-psychotherapy.html .  
 19 MDMA-assisted therapy sessions demonstrated the greatest efficacy when conducted 
two-three times annually.  See Michael Mithoefer ET AL., Safety and Efficacy of±3, 4-
methylenedioxymethamphetamine-Assisted Psychotherapy in Subjects with Cronic, Treatment-
Resistant Posttraumatic Stress Disorder, 25 J. OF PSYCHOPHARMACOLOGY 439 (2011).  
 20 See NAT’L INSTITUTE OF HEALTH, WHAT WE KNOW AND DON’T KNOW ABOUT MDMA: A 
SCIENTIFIC REVIEW (2001). 
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research on the efficacy, safety, and necessity of MDMA-assisted therapy.
21
  This 
comes as a result of the current state of veteran treatment effectiveness, which cannot 
suppress the growing prevalence of the disorder.
22
 
Though Veteran Affairs has provided crucial life sustaining—and often 
lifesaving—treatments to returning soldiers, the substantial and ever-increasing rates 
of veteran suicides, drug addictions, and criminal behavior indicate a need for broader 
options in treatment.
23
  One of the most profound discoveries uncovered through 
MDMA-assisted psychotherapy research is MDMA’s facilitation of the alleviation of 
addictive behavior in subjects, and, as a result, an alleviation of addictions in 
general.
24
  Addiction is one of the key symptoms of posttraumatic stress disorder, and 
drug abuse plays a large role in the other afflictions suffered by veterans, namely 
criminal activity and a high rate of suicide.
25
  If there is any hope of treating this 
debilitating psychotic phenomenon—or at least containing its rapid growth and 
addressing its profound depth—alternative remedies as a means must not be ignored 
for a normative end.
26
  
Accordingly, this article will argue that physicians must be able to treat PTSD 
victims through MDMA-assisted psychotherapy, an alternative remedy to PTSD 
treatment that has shown overwhelming promise in domestic and international 
medical research.  In doing so, it will first discuss 21 U.S.C.A. § 812, which labels 
MDMA as a Schedule I substance and prohibits healthcare professionals from using 
MDMA-assisted psychotherapy to treat PTSD victims.
27
  Next, the article will assert 
that the Drug Enforcement Agency (“DEA”) erroneously categorized MDMA as a 
substance lacking an accepted medical use and lack of safety under medical 
supervision.
28
  The article will set out studies, domestic and international, where 
clinical testing of MDMA-assisted therapy to treat PTSD have been met with 
                                                          
 21 Treating PTSD with MDMA-Assisted Psychotherapy website: 
http://www.mdmaptsd.org/news.html.  
 22 See Cukor ET AL., Emerging treatments for PTSD, 29 CLIN. PSYCHOLOGY REV. 715 
(2009). 
 23 Jack Gilbert, Veterans are being given MDMA to help them forget about war, Vice News 
(April 22, 2014, 1:00 PM) https://news.vice.com/article/veterans-are-being-given-mdma-to-
help-them-forget-about-war.   
 24 See Maia Szalavitz, Ecstasy as Therapy: have some of its negative effects been 
overblown?, Time (Feb. 18, 2011) http://healthland.time.com/2011/02/18/ecstasy-as-therapy-
have-some-of-its-negative-effects-been-overblown/;  See also Moreno-Lopez, et. al., Neural 
Correlates of the Severity of Cocaine, Heroin, Alcohol, MDMA and Cannabis Use in 
Polysubstance Abusers: A Resting-PET Brain Metabolism Study, PLOS One (June 29, 2012).   
 25 See Tanielian & Jaycox, Invisible Wounds of War: psychological and cognitive injuries, 
their consequences, and services to assist recover, RAND Center for Military Policy Research 
(2008).   
 26 See Brian Anderson, The agony of ecstasy: the quiet mission to fight PTSD with MDMA, 
Vice News (August 16, 2011)  http://motherboard.vice.com/blog/the-agony-and-the-ecstasy-
the-quiet-mission-to-fight-ptsd-with-psychedelic-drugs; see also John Richards, Amphetamine 
derivatives, 5 Nova Science 81 (2006). 
 27 Controlled Substances Act, 21 U.S.C. § 812 (2009). 
 28 Id. 
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overwhelmingly positive results.  Finally, the article will argue that MDMA’s 
accepted medical use, low physical and psychological dependence, and known safety 
under medical supervision support its classification as a Schedule III under the CSA, 
and that the 1986 classification of MDMA as a Schedule I narcotic was, and continues 
to be, an arbitrary and capricious agency interpretation of an otherwise viable piece of 
congressional legislation. 
 
II.  BACKGROUND 
A. Brief History of MDMA: Origins, Therapeutic Uses, and Cultural Impact. 
In 1914, the German pharmaceutical company Merck & Co. patented the substance 
3, 4-methylenedioxymethamphetamine, commonly known as MDMA.
29
 The origins 
of its synthesis are unclear: some assert that the purpose behind Merck’s patent was 
to create an anorectic or diet suppressant, while others suggest that Merck utilized 
MDMA as a precursor to hydrastinine, a haemostatic drug.
30
 Some evidence suggests 
that both American and German researchers resynthesized MDMA in the 1950s while 
seeking to create stimulants for Air Force pilots, however this fact is also contested.
31
   
The first officially documented experiments involving MDMA in the United States 
occurred in a U.S. military-sponsored animal study in 1953.
32
  The results of the study 
remained classified until 1972.
33
  In this study, researchers investigated the lethal 
dosage levels (“LDs” or “LD/50s”) of mescaline and seven analogs in five separate 
species of mammals:  mice, rats, dogs, guinea pigs, and monkeys.
34
  The core purpose 
of the study was to identify a lethal dosage of the substances in mammals.
35
 For 
obvious ethical reasons, however, the lethal dosage levels in humans could only be 
inferred.
36
  
In 1965, Alexander Shulgin, a chemist working at Dow Pharmaceutical Company, 
resynthesized MDMA.
37
  Shulgin then published the first study testing MDMA’s 
                                                          
 29 See A.C. Parrott, Human Pharmacology of Ecstasy: A Review of 15 Years of Empirical 
Research, 16 HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL 557 (2001). 
 30 Bernschneider-Reif, et al., The origin of MDMA (“Ecstasy”) – separating the facts from 
the myth (2006).   
 31 Id. 
 32 Id. 
 33 See Hardman et al., Relationship of the structure of mescaline and seven analogs to 
toxicity and behavior in five species of laboratory animals, 25 Toxicology and Applied 
Pharmacology 299 (1972). 
 34 See Alexander Shulgin, History of MDMA, in ECSTASY: CLINICAL, PHARMACOLOGICAL 
AND NEUROLOGICAL EFFECTS OF THE DRUG MDMA 1, 1-20 (1990). 
 35 Hardman, supra note 33.   
 36 Id. 
 37 See Shulgin, supra note 34. 
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psychotropic effects in human subjects.
38
  This study compared the effects of MDMA, 
3,4-Methylenedioxyamphetamine (“MDA”), and 2-(5-Methoxy-1H-indol-3-
yl)ethanamine
 (“mexamine”) on human subjects.39  Shulgin’s study concluded that 
MDMA had a higher threshold than MDA,
40
 and further that the substance 
“appear[ed] to evoke an easily controlled altered state of consciousness with emotional 
and sensual overtones.  It can be compared…to psilocybin, devoid of the hallucinatory 
component, or to low levels of MDA.” 41 Additionally, Shulgin acknowledged a need 
for further acute studies of psychotropics in human subjects, specifically in regards to 
MDMA’s potential effect on mental illness.42  
Two years later, researchers investigated MDMA’s pharmacological properties in 
humans.
43
  In 1978, Dr. George Greer published a clinical study whereby 
experimenters administered MDMA in humans.
44
  Greer administered low level of 
MDMA to 29 patients in a medical setting.
45
  The test sought to curtail “drug abuse 
problems, facilitate communication and intimacy between people involved in emotion 
relationships, and…as an adjunct to insight-oriented psychotherapy.”46  The test 
produced some undesirable side effects, none of which were serious and none that 
lasted longer than a week.
47
 These included increased blood pressure and heart rate 
over the span of two hours.
48
  Desirable side effects included alleviation of symptoms 
in subjects with DSM-III psychological disorders, “relieving low self-esteem and 
increasing self-acceptance and self-confidence,” and relief of physical ailments such 
as back pain.
49
 
Around the same time, researchers throughout the United States began 
administering MDMA in the therapeutic setting, recording its physical and 
psychological effects on human patients suffering with psychological disorders.
50
  
Undesirable physical effects, identical to those identified in Dr. Greer’s 1976 study, 
                                                          
 38 See Alexander Shulgin & Nichols, D.E., Characterization of Three New Psychomimetics, 
74 PSYCHOPHARMACOLOGY OF HALLUCINOGENS 83 (1978). 
 39 See Shulgin, supra note 34. MDA came into the view of medical researchers for its 
potential in treating various symptoms of Parkinson’s disease.  Id.  
 40 Id.  
 41 Id. 
 42 See Shulgin, supra note 38.   
 43 See Shulgin, supra note 38. 
 44 See e.g., George Greer, MDMA: A New Psychotropic Compound and Its Effects in 
Humans (1983). 
 45 Id.   
 46 See Shulgin, supra note 38. 
 47 See Greer, supra note 44. 
 48 Id.  
 49 Id.  
 50 See Philip Wolfson, Meeting at the Edge with Adam: a Man for All Seasons, 18 J. OF 
PSYCHOACTIVE DRUGS 329 (1986). 
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were uniformly reported.
51
  These included elevated heart rate and blood pressure, as 
well as the suppression of appetite.
52
  No instances of death, injury, or long-term 
neurological deficiency were reported.
53
 
Subjectively, volunteers identified strong improvements in “self-understanding,” 
spiritual and personal growth, a lessening of an otherwise powerful desire to abuse 
drugs or alcohol, and a renewed drive to address personal issues.
54
 Other accounts 
indicate an increased desire and capacity to suppress drug abuse, heightened 
sensations of self-worth, and a transcendent sense of calm that persisted well beyond 
the conclusion of the experiments.
55
  MDMA’s significant psychological effects on 
patients suffering with depression, drug or alcohol abuse, and sexual dysfunction 
prompted a worldwide interest in the medical benefits of MDMA in the early 1970’s56   
Following early research, the general consensus in the medical community was 
that “MDMA is reasonably safe, produces positive mood changes in users, does not 
cause negative problems if used sparingly and episodically, and is without evidence 
of abuse.”57  That being said, the scientific data through the 1970’s and early 80’s had 
yet to conclusively show that MDMA use did not produce long-term neurotoxicity.
58
  
Nonetheless, as one study concluded, “MDMA, at the doses tested, has remarkably 
consistent and predictable psychological effects that are transient and free of 
clinically-apparent major toxicity.”59 
As its medical and social popularity increased throughout the 1970’s and early 
1980’s, the Health and Human Services Department urged the continuation and 
expansion of MDMA research.
60
  In spite of this, the FDA refrained from permitting 
any Investigational New Drug (“IND”) license to medical researchers seeking to 
research MDMA, thus hindering the potential for expanded clinical research in 
humans.
61
  With the medical community’s desire for greater MDMA research came 
                                                          
 51 See Harold Kalant, Pharmacology and Toxicology of “Ecstasy” and Related Drugs, 165 
CANADIAN MED. J. 917, 925 (2001); see also Sotiria Bexis & James Docherty, Effects of MDMA, 
MDA and MDEA on Blood Pressure, Heart Rate, Locomotor Activity and Body Temperature in 
the Rat Involve α-Adrenoceptors, 147 J. OF PHARMACOLOGY, 926 (2006).  
 52 See Shulgin, supra note 38. 
 53 Id. 
 54 George Greer & Requa Tolbert, Subjective Reports of the Effects of MDMA in a Clinical 
Setting, 18 J. OF PSYCHOACTIVE DRUGS 319 (1986).  
 55 Marsha Rosenbaum & Rick Doblin, Why MDMA Should Not Have Been Made Illegal, in 
THE DRUG LEGALIZATION DEBATE (James A. Inciardi ed., 1991). 
 56 See Shulgin, supra note 38. 
 57 Joseph Downing, The psychological and physiological effects of MDMA on Normal 
Volunteers (1986).   
 58 Id. 
 59 Id. 
 60 See id. 
 61 Id. 
 
2016] MENDING INVISIBLE WOUNDS 279 
 
public controversy and subsequent Congressional legislation, acting in conjunction to 
bring “clinical studies with MDMA…to a complete halt.”62 
 
B. Public Opposition, the Controlled Substances Act, and the Grinspoon Case 
 As scientific knowledge of MDMA’s benefits began to grow, so too did its 
reputation as a dangerous “mind-altering psychedelic.”63  In 1981, the countercultural 
publication Wet ran a story promoting the use of MDMA.
64
  The publication caused 
great controversy, and initiated a steeply divided debate on the medical benefits, 
harms, and legality of MDMA.
65
 
By 1983, MDMA had grown popular in the American south.
66
  In Texas, for 
example, several night clubs and bars were known to distribute MDMA to patrons.
67
  
The popularity of the substance among young club-goers attracted the attention of 
cocaine dealers, who began organizing complex and far-reaching sale structures of 
MDMA.  As a result, “distribution grew and recreational, as opposed to the more 
therapeutically oriented use, increased dramatically.
 68
 
A few months later, open sales in Texas prompted legislators to push scheduling 
of MDMA.  Shortly thereafter, the DEA filed its Notice of Proposed Rulemaking to 
the Federal Register, “announcing its intention to place MDMA in Schedule I.”69  As 
legislators and federal officials began their march toward full-force illegalization, 
medical professionals mobilized in resistance to this possibility.  A “small but 
dedicated group of medical professionals maintained that MDMA was too valuable in 
therapy” to merely dismiss it.70  Other medical researchers, however, along with the 
U.S Department of Justice, raised concerns of abuse and potential neurotoxicity in 
humans.
71
 
As MDMA gained medical and cultural popularity in the 1970’s and throughout 
the early 1980’s, researchers quickly began to focus on what it perceived to be 
“potential neurotoxic qualities.”72  The Food and Drug Administration (FDA) 
                                                          
 62 Id. 
 63 See Shulgin, supra note 38. 
 64 See generally Ecstasy: Everything Looks Wonderful When You’re Young and On Drugs, 
WET MAGAZINE,  p. 76 (1981). 
 65 See Shulgin, supra note 38. 
 66 How the Starck Club Changed Dallas, D Magazine (2013). 
 67 Rosenbaum, supra note 55.   
 68 Id. 
 69 Marshal Rosenbaum and Rick Doblin, Why MDMA Should Not Have Been Made Illegal, 
THE PSYCHEDELIC LIBRARY, http://www.psychedelic-library.org/rosenbaum.htm (last visited 
March 24, 2016). 
See Shulgin, supra note 34. 
 71 See id.; see also E. O’Hearn et al., Methylenedioxyamphetamine and 
Methylenedioxymethamphetamine Cause Selective Ablation of Serotonergic Axon Terminals in 
Forebrain, THE J. OF NEUROSCIENCE, 2788, 2800 (1988). 
 72 Id.  
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“temporarily scheduled” the drug as a dangerous narcotic in 1985, refusing to approve 
it for interstate marketing approval.
73
   
In its 1987 Notice of Proposed Rulemaking, the DEA asserted that MDMA “lacked 
any legitimate medical uses, significantly threatened the health of users, and had a 
high potential for abuse.”74  In response, medical professionals with experience in 
conducting MDMA-assisted therapy throughout the United States fiercely opposed 
the “unjustified” agency determination.75 These doctors asserted that MDMA was a 
“tremendous aid” to alleviating the symptoms of several devastating psychiatric 
conditions, and sought to support that assertion data.
76
 
In spite of strong opposition from the medical community, DEA director John 
Lawn held an emergency scheduling hearing, where he announced that MDMA was 
an “immanent hazard to public safety,” and placed it under Schedule I.77 In response, 
Dr. Lester Grinspoon, a professor of Psychiatry at Harvard University, brought suit 
against the DEA administrator.
78
  Dr. Grinspoon won his case before the Second 
Circuit Court of Appeals because, as the Second Circuit stated, “FDA approval is not 
determinative of a lack of acceptable medical use.”79 Thus, the scheduling was 
remanded to the DEA director for reconsideration.
80
  Three months later, however, 
the DEA reissued its ruling, and once again classified MDMA as a schedule I narcotic 
with no accepted medical use.
81
 
On March 23, 1988 the DEA placed MDMA into Schedule I under the Controlled 
Substances Act (“CSA”) The CSA, which Congress passed in 1970, set out to 
accomplish three main goals: (1) to prevent drug abuse and dependence; (2) provide 
treatment and rehabilitation for drug abusers and dependents; and (3) strengthen law 
enforcement in the context of drug abuse.
82
  The CSA created five classifications for 
                                                          
 73 See Greer & Tolbert, supra note 44. 
 74 21 U.S.C. § 812 (2009).  
 75 See 53 FR 5156-01 (1988). Schedules of Controlled Substances; Scheduling of 3,4-
Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act, 
53 Fed. Reg. 5156 (February 22, 1988)(to be codified at 21 CFR pt 1308). 
 76 Id. 
 77 The New York Times, U.S. Will Ban ‘Ecstasy,’ A Hallucinogenic Drug, 
http://www.nytimes.com/1985/06/01/us/us-will-ban-ecstasy-a-hallucinogenic-drug.html (last 
visited March 24, 2016).  
 78 Grinspoon v. Drug Enf’t Admin., 828 F.2d 881, 882 (1st Cir. 1987). 
 79 Id. 
 80 Richard Glen Boire, The Politics of Medicine: the Schedluing of MDMA, CENTER FOR 
COGNITIVE LIBERTY & ETHICS, http://www.cognitiveliberty.org/dll/mdma_scheduling_
history.htm (last visited March 24, 2016). 
 81 Id. 
 82 Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. No. 91-513, 84 
Stat. 1236 (1970).  
 Sec. 101. The Congress makes the following findings and 
declarations: 
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varying substances based on the drug’s potential for abuse, dependence, and accepted 
medical uses.
83
 In a final scheduling hearing, Director Lawn concluded that pursuant 
to the purposes of the CSA, and due to a lack of an accepted medical use and lack of 
known safety under medical supervision, MDMA would hereinafter be classified as a 
Schedule I.
84
 
 
C. Veteran PTSD, Current Treatments, and MDMA-Assisted Psychotherapy
85
 
                                                          
(1) Many of the drugs included within this title have a useful and legitimate medical 
purpose and are necessary to maintain the health and general welfare of the American 
people.  Id.  
 83  United States Drug Enforcement Administration (DEA), Drug Scheduling, 
http://www.dea.gov/druginfo/ds.shtml (last visited March 24, 2016) .; Schedule I substances are 
those considered to have a high potential for abuse, no accepted medical use, and a lack of 
accepted safe use under medical supervision.  Id.   
 84 Schedules of Controlled Substances; Scheduling of 3,4-
Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act, 
supra note 76.; Remand, 53 Fed.Reg. 5156 (1988). 
 a) Establishment 
There are established five schedules of controlled substances, to be known as schedules 
I, II, III, IV, and V. Such schedules shall initially consist of the substances listed in this 
section. The schedules established by this section shall be updated and republished on 
a semiannual basis during the two-year period beginning one year after October 27, 
1970, and shall be updated and republished on an annual basis thereafter. 
(b) Placement on schedules; findings required 
Except where control is required by United States obligations under an international 
treaty, convention, or protocol, in effect on October 27, 1970, and except in the case of 
an immediate precursor, a drug or other substance may not be placed in any schedule 
unless the findings required for such schedule are made with respect to such drug or 
other substance. The findings required for each of the schedules are as follows: 
(1) Schedule I-- 
(A) The drug or other substance has a high potential for abuse. 
(B) The drug or other substance has no currently accepted medical use in treatment in 
the United States. 
(C) There is a lack of accepted safety for use of the drug or other substance under 
medical supervision. 
(2) Schedule II-- 
(A) The drug or other substance has a high potential for abuse. 
(B) The drug or other substance has a currently accepted medical use in treatment in the 
United States or a currently accepted medical use with severe restrictions. 
 85 The DEA has recently permitted a study of MDMA for patients suffering with anxiety 
due to life threatening illnesses.  “The height of the drug war in 1985, the agency classified 
MDMA in Schedule I under the Controlled Substances Act. The federal government considers 
Schedule I drugs to be among the "most dangerous," with no known medical benefits and the 
potential for "severe psychological or physical dependence." That decision overruled a previous 
recommendation by the DEA's chief administrative law judge that the drug be placed in 
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This scheduling placed severe restrictions on MDMA research.  For example, for 
several decades the FDA refused to permit experimentation because of a “concern for 
the health of volunteers.”86  Further, therapists and physicians abandoned clinical use 
and research of MDMA in fear of losing their license and damaging their 
reputations.
87
  Thus, a substance with a substantial record of therapeutic benefits was 
abandoned as a result of the DEA’s ruling. 
Today, post-traumatic stress disorder is a highly prevalent psychological disorder 
in veterans of war.
88
   The symptoms of PTSD are numerous and severe.  These 
include vivid flashbacks, hallucinations, insomnia, nightmares, hyperarousal, negative 
changes in beliefs or mood, and other drastic behavioral changes.
89
  These symptoms 
can be crippling to veterans seeking to assimilate to civilian life.
90
 
For example, Tim Amoroso is a 24-year-old ex-Army Ranger who fought in 
Afghanistan.
91
  Upon returning home to New Hampshire, Tim battled with “memories 
of looking for body parts” as a result of experiencing a suicide bomb attack on his 
platoon.
92
  Like hundreds of thousands of returning vets, Tim turned to the VA in an 
attempt to eradicate these vicious memories.
93
  
The VA prescribed Tim with antidepressants and antianxiety medications, neither 
of which brought meaningful relief.
94
  The lack of efficacy of these medications led 
Tim to seek alternative remedies to treat his PTSD.
95
  One summer, Tim purchased 
MDMA and ingested it under the supervision of a friend.
96
  According to Tim, the 
positive effect of the MDMA outweighed anything he had experienced on 
                                                          
Schedule III, which would have allowed doctors to continue using it in therapy.” See Wing, 
infra note 170. 
 86 Constance Scharff, Ph.D., Does MDMA Have Psychotherapeutic Potential, 
http://www.constancescharff.com/?p=248 (last visited March 24, 2016). 
 87 Marsha Rosenbaum and Rick Doblin, supra note 55.  
 88 Veterans and PTSD, Veterans statistics: PTSD, Depression, TBI, Suicide, 
http://www.veteransandptsd.com/index.html (last visited March 24, 2016) 
 89 U.S. Department of Veterans Affairs, PTSD: National Center for PTSD, 
http://www.ptsd.va.gov/public/PTSD-overview/basics/symptoms_of_ptsd.asp (last visited 
March 24, 2016). 
 90 Id.  
 91 Alan Zarembo, Exploring Therapeutic Effects of MDMA on Post-Traumatic Stress 
Disorder, L.A. TIMES, (March 15, 2014), http://articles.latimes.com/2014/mar/15/local/la-me-
mdma-20140316.  
 92 See id. 
 93 Id. 
 94 Id. 
 95 Id. 
 96 Id. 
 
2016] MENDING INVISIBLE WOUNDS 283 
 
antidepressants.
97
  “I feel like I found meaning again,” said Tim.  “My life wasn’t as 
bad as I thought it was.”98   
Since 2001, over 1.5 million American soldiers like Tim have been deployed to 
Afghanistan or Iraq.
99
  Upon returning from deployment, Veteran Affairs estimates 
that 20-30% of soldiers suffer from post-traumatic stress disorder, major depressive 
disorder, traumatic brain injury, or some combination of the three.
100
  Until recently, 
the hidden nature of these wounds has hindered research and subsequent 
understanding of this mental disorder.
101
 
All Operation Iraqi Freedom (“OIF”) and Operation Enduring Freedom (“OEF”) 
veterans are eligible to receive aid from the VA.
102
  That being said, young veterans 
face several challenges in accessing quality mental treatment from the VA.
103
  For 
example, the VA operates on a fixed budget, and cannot be expected to keep pace with 
the rapid amount of OIF/OED and Vietnam veterans seeking treatment.
104
  Further, 
VA services may give higher priority to physically-disabled veterans.  Also, many 
veterans do not live close to a VA facility.
105
  
Additionally, current PTSD treatments have not been met with meaningful 
success.
106
  The VA offers four different services for PTSD treatment: one-on-one 
mental health assessment and testing, medications, individual and family 
psychotherapy, and group therapy.
107
  Regardless of the available treatments, the 
average PTSD victim still qualifies for the disease four months after treatment.
108
  
Psychiatrists, physicians, and medical researchers question the efficacy of Prozac, 
                                                          
 97 Id. 
 98 Id. 
 99 RAND Center for Military Health Policy Research, Invisible Wounds: Mental Health and 
Cognitive Care Needs of America’s Returning Veterans (2008), http://www.rand.org/
content/dam/rand/pubs/research_briefs/2008/RAND_RB9336.pdf . 
 100 Id. 
 101 Id. 
 102 U.S. Department of Veterans Affairs, Returning Service Members (OEF/OIF/OND), 
http://www.oefoif.va.gov/healthcare.asp (last visited March 25, 2016). 
 103 RAND Center for Military Health Policy Research, supra note 99, at 4.  
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 107 U.S. Department of Veteran Affairs, PTSD Treatment Programs in the U.S. Department 
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programs.asp (last visited March 25, 2016). 
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Paxil, and Zoloft in treating PTSD symptoms.
109
 Furthermore, research suggests that 
antidepressants are often no more effective than a placebo in treating veterans who 
suffer with PTSD.
110
  Ineffective treatments and the common practice of self-
medication undoubtedly aggravate the fragile mental state of veterans with the 
disorder.
111
  In an effort to address this growing problem, the FDA recently approved 
a study of MDMA-assisted psychotherapy in treating veterans, police officers, and 
firefighters who suffer with PTSD.
112
  Since MDMA remains in Schedule I, however, 
psychiatrists may not conduct MDMA-assisted therapy sessions on an as-needed 
basis, and access for veterans is limited to these types of seldom-approved volunteer 
studies.
113
 
 
III.  ACCEPTED MEDICAL USE OF MDMA TO TREAT POST-TRAUMATIC STRESS 
DISORDER IN VETERANS 
A. Accepted Medical Use Defined 
 Schedule I substances are those that the DEA determines lack an accepted 
medical use, have a high potential for abuse, and cannot be used safely under medical 
supervision.
114
  The CSA does not define “accepted medical use” in the definition 
section of the act.
115
  Thus, its meaning has been the subject of much debate since the 
act’s promulgation.116   
There are two main inquiries the DEA will undertake in determining whether a 
substance has an accepted medical use.  First, the DEA considers five distinct factors 
                                                          
 109 Zoloft, for example, has been found to be effective in female patients, but not in male. 
Michael A. Hertzberg, M.D., et al., Lack of Efficacy for Fluoxetine in PTSD: A Placebo 
Controlled Trial in Combat Veterans, 12 ANNALS OF CLINICAL PSYCHIATRY 101 (2000). 
 110 Jay C. Fournier, M.A., et al., Antidepressant Drug effects and Depression Severity: A 
Patient-Level Meta-Analysis, 303 JOURNAL OF AM. MED. ASS’N 47 (2009). 
 111 See Alexander McFarlane, Epidemiological Evidence About the Relationship Between 
PTSD and Alcohol Abuse, 23 ADDICTIVE BEHAVIORS 813 (1998); see also Paige Ouimette, et 
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 112 Michael C. Mithoefer, et al., The safety and efficacy of ±3,4-
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resistant posttraumatic stress disorder: the first randomized controlled pilot study, 25 J. OF 
PSYCHOPHARMACOLOGY 439 (2010). Drug Policy Alliance, Healing a Broken System: Veterans 
and the War on Drugs (November 2012), http://www.drugpolicy.org/sites/default/
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 114 21 U.S.C. § 812 (2009). 
 115 Marijuana Scheduling Petition, 57 Fed. Reg.10,499, 10,504 (March 26, 1992). (stating 
regrettably, the Controlled Substances Act does not speak directly to what is meant by ‘currently 
accepted medical use). 
 116 Id., at 10,503. 
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of the substance.  Second, the DEA considers whether the substance has FDA 
approval.
117
   
The DEA will consider the following five factors to determine whether a substance 
has an accepted medical use in the United States:  (1) the substance’s chemistry is 
known and reproducible; (2) there are adequate safety studies; (3) there are adequate 
and well controlled studies determining efficacy; (4) the drug is accepted by qualified 
experts; and (5) the scientific evidence is widely available.
 118
 The DEA will conclude 
that a substance has an accepted medical use if all five of these factors are met.
119
   
 
B. DEA Findings and Rationale in Scheduling MDMA 
 In order to determine the DEA’s rationale for placing MDMA in Schedule I, 
an analysis of its 1988 final ruling is required.  In that ruling, Director Lawn 
extrapolated upon each of the five enumerated factors, ultimately concluding that 
MDMA deserved Schedule I classification.
120
   
First, the administrator noted that MDMA lacked FDA approval.  Director Lawn 
relied upon the fact that a single FDA pharmacologist, “experienced in evaluating the 
safety and efficacy of drugs,” found that current research provided “no data or 
evidence to support a claim that MDMA is effective as a therapeutic agent.”121 
Nonetheless, Director Lawn correctly indicated that fact that a drug is not lawfully 
approved for marketing is a “factor to be considered in determining whether a 
substance lacks accepted safety for use under medical supervision, but is not 
conclusive.”122 
 He further noted that MDMA had not been subject to sufficient animal testing to 
support trials in humans, stating that the “published literature contains no references 
                                                          
 117 Denial of Petition To Initiate Proceedings To Reschedule Marijuana, 76 Fed. Reg. 40,552, 
40,559 (July 8, 2011)(to be codified at 21 CFR pt. 2). 
 118  See 76 Fed. Reg. 40552 (2011); See id.  For the DEA to find that a substance has a 
currently accepted medical use under the CSA, all five factors must be met. 76 Fed. Reg. 40552 
(2011); All. for Cannabis Therapeutics v. Drug Enf’t Admin., 15 F.3d 1131, 1134 (1994).  “The 
current test dates back to a 1992 order denying NORML's 1973 rescheduling petition. In 
announcing the test, DEA Administrator Robert C. Bonner explained that it was derived from 
the Food, Drug and Cosmetic Act. Bonner “[t]he pattern of initial scheduling of drugs in the 
Controlled Substances Act, viewed in light of the prior legal status of these drugs under the 
FDCA, convinces me that Congress equated the term ‘currently accepted medical use in 
treatment in the United States’ as used in the Controlled Substances Act with the core FDCA 
standards for acceptance of drugs for medical use.” Denial of Petition to Initiate Proceedings 
To Reschedule Marijuana, supra note 118. Importantly, however, Bonner cautioned that “not 
… every FDCA requirement … is pertinent to scheduling determinations under the Controlled 
Substances Act,” so it appears to be possible for a drug that does not have FDA approval to be 
found to have a currently accepted medical use under the DEA's test. Marijuana Scheduling 
Petition, supra note 116, at 10,506.”  Id. 
 119 Marijuana Scheduling Petition, supra note 115, at 40,552.  
 120 Schedules of Controlled Substances; Scheduling of 3,4-
Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act, 
supra note 76, at 5156. 
 121 See 53 FR 5156-01 (1988). Id., at 5157. 
 122 Id., at 5158. 
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to the clinical use of MDMA nor animal studies to indicate such clinical use.”123  
Without clinical studies, the Director asserted that all information regarding long term 
neurotoxicity in humans is mere speculation, and thus that there was no way of 
knowing whether it was safe.
124
  Director Lawn explained the safety concern as 
follows: 
 
Studies in animals [show] that MDMA produces long term serotonergic 
nerve terminal degeneration. Such effects would not necessarily be 
observed immediately in individuals who had taken the drug. The long term 
safety of MDMA has not been established through reproductive or 
carcinogenic studies. Since MDMA has not been shown to be effective for 
treating a specific condition, it is impossible to make a risk/benefit analysis 
of the drug. Two psychiatrists who testified on behalf of the agency in the 
proceedings indicated that they would not administer MDMA to humans 
until and unless further studies had been conducted to establish its safety 
and lack of neurotoxicity.
125
 
Additionally, the Director observed that no data presented at the hearing had the 
potential for peer review, and that the evidence available was “purely anecdotal.”126 
He noted that the evidence in the record before the DEA merely demonstrated that a 
few psychiatrists had administered MDMA to approximately 200 subjects.
127
 “These 
physicians were not conducting scientific studies with MDMA, they were 
administering the drug as if it was an approved product which had been scientifically 
tested.”128  Thus, he concluded that the evidence presented was anecdotal accounts 
and not “scientific” so as to demonstrate an accepted medical use.129 
Further, he asserted that MDMA lacked any “therapeutic use,” citing a “panel of 
international experts” who allegedly arrived at the same conclusion.130  Thus, the 
director concluded that the published scientific and medical literature as of 1988, 
coupled with information from the files of the Food and Drug Administration (i.e. a 
lack of interstate marketing approval), “did not establish or support claims of 
                                                          
 123 Id.  The director concluded that “[t]he published literature contains no references to the 
clinical use of MDMA nor animal studies to indicate such a clinical use. Recognized texts, 
reference books and pharmacopeia contain no references to the therapeutic use of MDMA. The 
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therapeutic use of MDMA, as an adjunct to psychotherapy, in treatment in the United 
States.”131  Accordingly, Director Lawn concluded that MDMA had no accepted 
medical use and deserved Schedule I status.
132
 
Today, pure MDMA has been proved to be “sufficiently safe” when ingested a 
minimal number of time over a long period.
133
  MDMA-assisted psychotherapy 
follows this trajectory, as MDMA ingestion occurs once during a three-month 
period.
134
  Additionally, further animal testing has provided a foundation for MDMA 
testing in humans.
135
  Recent studies have been successfully completed in the medical 
setting, demonstrating a plausibly degree of certainty toward the safety of the tests.
136
  
Evidence is not purely anecdotal; the sample sizes in modern experiments range from 
12-60 human test subjects, and the scope of MDMA research spans the globe.
137
  
Finally, Director Lawn fails to indicate the rationale of the “panel of international 
experts,” or what, if any, evidentiary basis they provided for their conclusion.138  On 
the contrary, the evidence today demonstrates a greater international interest in curing 
PTSD through MDMA-assisted psychotherapy than our national interest.  
 
C.  MDMA’s Accepted Medical Use in the Context of Medically Assisted 
Psychotherapy 
First, MDMA’s chemistry is known and reproducible today.139  According to the 
DEA, a substance’s chemistry is known and reproducible when it can be reproduced 
into dosages which can be standardized.
140
  This standard is elucidated by several 
hearings regarding the accepted medical use of marijuana.
141
  For example, in 
concluding that the chemistry of marijuana is not known or reproducible, the DEA 
reasoned that “over 400 different chemicals have been identified in the plant,” and that 
                                                          
 131 Id. 
 132 Id. 
 133 Students for Sensible Drug Policy, SSDP Psychedelic Legalization Toolkit, 
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“proportions of concentrations differ from plant to plant, depending on growing 
conditions, age of the plant, harvesting and storage factors.”142 
Unlike marijuana, the chemical structure and function of MDMA does not depend 
on external conditions, nor is it composed of a significant amount of varying 
chemicals.
143
 These four chemicals combine to synthesize MDMA in its pure 
form.
144
  Ecstasy, the illicit street drug which utilizes PMK to produce a psychoactive 
effect, includes a much higher amount of chemicals and adulterous additives.
145
  
Accordingly, the chemical structure of pure MDMA is well known, and is easily 
reproducible in a clinical setting and in comparison with marijuana or other Schedule 
I substances.
146
  
Second, medical researchers around the world have conducted a significant 
amount of studies regarding MDMA’s safety.147  As stated by the DEA in 1992, “there 
must be adequate studies, by all methods reasonably applicable, to show the 
pharmacological and toxicological effects of the drug” in order to know its safety.148  
These include animal studies and clinical tests with large number of humans.
149
  The 
studies “need not be well controlled, but must be adequate.”150 
A profusion of studies testing the effects of MDMA on animal subjects has 
occurred since the 1950’s.151  In 1986, researches at the Medical College of Virginia 
tested the self-administration of MDMA in rhesus monkeys.
152
 In 2001, Johns 
Hopkins University tested the cognitive performance of MDMA-treated rhesus 
                                                          
 142 Id. at 10507 
 143 MDMA, specifically 3,4-Methylenedioxy-N-Methylamphetamine, is the sole 
psychoactive agent in the chemical, and contains no other chemicals that produce the 
psychoactive effect.  There are four “principle precursors” used in the manufacture of MDMA: 
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291, 291 (1986). 
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 148 Grinspoon, 828 F.2d at 881. 
 149 Id. at 894-95. 
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monkeys.
153
  A study of primate PET-scans before and after administration of a 
neurotoxic level of MDMA revealed its effect on serotonin in the primate brain.
154
 
The lethal dosage level of MDMA has not been determined in humans.  
Nonetheless, researchers have conducted many clinical tests on a significant number 
of human subjects.
155
 In 1978, clinical psychiatrist Alexander Shulgin administered 
MDMA to fellow therapists in an uncontrolled study of the subjective effects of 
MDMA.
156
  Shulgin noted the physiological effects on heart rate and body 
temperature, as well as its mood elevated and spiritual qualities.
157
  No toxic qualities 
in humans were identified or recorded.
158
 
In 1994, the National Institute of Health conducted a study on the neurotoxicity of 
MDMA in the human brain.
159
  The NIH study measured the neurotoxic effects of 
MDMA against physical characteristics of subjects, such as weight, height, sex, and 
personality traits.
160
  The test concluded that MDMA users had “lower scores on 
personality measures of impulsivity,” and that MDMA may have an effect on 
suppressing aggressive personality states.
161
 
In July of 2000, the University of Psychiatry in Zurich published a study of the 
psychological and physiological effects of MDMA on humans who had been 
pretreated with haloperidol, a substance used in treating schizophrenia and other 
psychiatric mood disorders.
162
  The study, which included 14 healthy subjects, 
concluded that MDMA produced an “affective state of well-being, with increased 
extroversion and socialability.”163  The study noted the physiological effect of 
MDMA on healthy individuals, listing an increase in blood pressure and heart rate, as 
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Sensitivity to Serotonergic Challenge, 27 NEUROPSYCHOPHARMACOLOGY 993, 995-996 (2001). 
 154 Sudhakar Selvaraj, et al., Brain Serotonin Transporter Binding in Former Users of 
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 155 Charles Grob, MDMA Research: Preliminary Investigations with Human Subjects, 9 
INT’L J. OF DRUG POL’Y 119, 121 (1998). 
 156 Id. 
 157 NAT. INST. OF HEALTH, ECSTASY: WHAT WE KNOW AND DON’T KNOW ABOUT MDMA 5 
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well as a heightened body temperature.
164
  The main complaints from subjects were 
fatigue, lack of appetite, and thirst, among others.
165
   
These studies comprise an adequate foundation through which the safety or danger 
of MDMA can be known.  A great deal of information regarding the dangers and 
benefits of MDMA has been unveiled over the last several decades, especially in 
contrast to the medical information available to the scientific community in 1988.  
Human clinical testing has demonstrated knowledge of the known risks and benefits 
of MDMA.
166
  These tests demonstrate an adequate safety level that supports an 
accepted medical use in the United States. 
Third, studies demonstrate the efficacy of MDMA-assisted psychotherapy in 
treating soldiers suffering from post-traumatic stress disorder.
167
 A recent double-
blind study conducted by the Medical University of South Carolina found a 30% 
reduction in the Clinically-Administered PTSD Scale (“CAPS”) as compared with 
those subjects receiving a placebo.
168
  Psychiatric researchers in Zurich conducted a 
similar study on MDMA-assisted psychotherapy in veterans suffering with PTSD.
169
  
This double-blind study indicated a lessening of PTSD victim CAPS scores after two 
months of MDMA-assisted psychotherapy sessions.
170
  Additionally, the efficacy of 
MDMA-assisted PTSD treatment was further analyzed in a 2007 evidence-based 
meta-analysis of the treatment.
171
 A randomized triple-blind comparative study of 
MDMA use in conjunction with therapy in firefighters and police officers suffering 
with PTSD has been approved by the FDA and is scheduled to occur in 2016.
172
 
The DEA conclusion that MDMA has “no therapeutic use in the United States” is 
no longer scientifically supported.
173
  In the specific context of the PTSD pandemic 
in our nation’s veterans, MDMA-assisted therapy is an effective means to combat 
otherwise untreatable symptoms.
174
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Fourth, the safety and efficacy of MDMA is supported by a community of reliable 
medical experts.
175
  Studies conducted by medical professionals in Zurich have 
determined the safety of MDMA-assisted psychotherapy in a clinical setting.
176
  
Psychiatric researchers in the United States have concluded that MDMA-assisted 
therapy can be conducted safely and with effective results in PTSD victims.
177
  The 
FDA has approved a triple-blind study of MDMA-assisted psychotherapy in the 
United States, the first of its kind since before it was illegalized in 1986.
178
  Further, 
experiments in Israel and Jordan also provide support for the safety and efficacy of 
MDMA-assisted therapy.
179
 
Fifth, the evidence supporting MDMA’s positive effect on post-traumatic stress 
disorder is widely available to researchers and the public.  In determining whether a 
drug is widely available to experts, courts analyze if there is “widely available 
scientific literature about the drug,
180
 “whether it is widely taught in medical 
schools
181
,” and “whether it is widely discussed by experts.”182 
At the time of the original scheduling in 1988, DEA director John Lawn correctly 
noted a lack of published literature referencing the clinical use of MDMA.
183
  Lawn 
pointed to two “unpublished studies supporting therapeutic use of MDMA.”184  
Further, Lawn indicated that recognized texts did not indicate the use of MDMA as a 
substance with therapeutic purposes.
185
 
Today, MDMA has fixed itself at the center of academic and medical discussion.  
Harvard Medical School plans to study the therapeutic effects of psychedelic 
substances on terminally ill patients.
186
    The FDA approved Harvard University’s 
McLean Hospital’s request to reinvigorate research programs incorporating 
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psychedelic medicine.
187
 Further, the prestigious scientific publication “Scientific 
American” has called for the United States to implement MDMA into therapy.188  The 
article correctly indicates that MDMA “had its origin in medical pharmacopeia.”189 
The ever-expanding pool of clinical studies and academic discussions , and the surge 
in MDMA-assisted psychotherapy studies for PTSD treatment, all indicate a changing 
landscape where the effects of MDMA-assisted therapy are widely available to 
psychiatrists and researchers in the medical field.
190
  Accordingly, in applying these 
five factors to the current scientific understand of MDMA, Schedule I classification 
must be reconsidered for a schedule that permits healthcare professionals to 
adequately address the debilitating symptoms of MDMA. 
 
IV.   APPLYING THE CHEVRON STANDARD TO DRUG ENFORCEMENT AGENCY 
SCHEDULING 
 
DEA regulatory action regarding the Schedule I classification can be viewed under 
the Chevron “arbitrary and capricious” framework.191  "The power of an 
administrative agency to administer a congressionally created . . . program necessarily 
requires the formulation of policy and the making of rules to fill any gap left, implicitly 
or explicitly, by Congress."
192
  If the statute creating a program is ambiguous, that 
ambiguity is viewed as an express delegation of legislative discretion to an agency.
193
  
Thus, “regulations are given controlling weight unless they are arbitrary, capricious, 
or manifestly contrary to the statute.”194 
Having established the ambiguity of the Controlled Substances Act as written by 
Congress, the issue of whether MDMA is erroneously scheduled must be viewed 
under the “arbitrary, capricious, or manifestly contrary to the statute” framework set 
out by the United States Supreme Court in Chevron.
195
  This is not exactly an issue of 
first impression; the First Circuit dealt with the merits of this exact issue in 1987, in 
                                                          
 187 John Horgan, Psychedelic Medicine: Mind Bending, Health Giving, NEW SCIENTIST (Feb. 
23, 2005), http://www.newscientist.com/article/mg18524881.400-psychedelic-medicine-mind-
bending-health-giving.html.  
 188 Roni Jacobson, Turn On, Tune in, Get Better: Psychedelic Drugs Hold Medical Promise, 
SCI. AM. (Sept. 1, 2014), http://www.scientificamerican.com/article/turn-on-tune-in-get-better-
psychedelic-drugs-hold-medical-promise. 
 189 Id. 
 190 Id. 
 191 Grinspoon, 828 F.2d 884; Chevron, U.S.A., Inc. v. NRDC, Inc., 467 U.S. 837, 844 (U.S. 
1984), Motor Vehicle Mfrs. Ass'n v. State Farm Mut. Auto. Ins. Co., 463 U.S. 29, 56 (U.S. 
1983). 
 192 Chevron, 467 U.S. at 843 (quoting Morton v. Ruiz, 415 U.S. 199, 231 (1974)). 
 193 Chevron, 467 U.S. at 843. 
 194 Id. at 844. 
 195 Id. 
 
 
2016] MENDING INVISIBLE WOUNDS 293 
 
the case of Grinspoon v. Drug Enforcement Administration.
196
  The court in 
Grinspoon analyzed whether the DEA administrator’s conclusion that MDMA had a 
high potential for abuse and lacked any accepted medical use was arbitrary and 
capricious.
197
  The court answered both questions in the negative.
198
  Nonetheless, 
the First Circuit’s conclusion faces seemingly insurmountable challenges when 
viewed in relation to the progress of recent MDMA research.
199
  
 
A.  The First Circuit Correctly Concludes that Director Lawn’s Findings Were Not 
Arbitrary and Capricious 
Immediately following the DEA’s ruling, psychiatrist and Harvard Medical 
Professor Lester Grinspoon petitioned the First Circuit to review Director Lawn’s 
classification.
200
  Dr. Grinspoon asserted four arguments in support of overturning the 
DEA ruling.  First, Dr. Grinspoon argued that the director misapplied the “accepted 
medical uses” standard and thus erroneously found MDMA to be one of the substances 
under § 812 that lack an accepted use.
201
  The final three reasons were premised on 
the notion that the scheduling was arbitrary and capricious and therefore must be 
vacated.
202
 
Though the First Circuit agreed with Dr. Grinspoon on the first issue, and thus 
reversed the judgment and ordered the DEA to reconsider its ruling, Dr. Grinspoon 
was unsuccessful in arguing that the DEA interpretation arbitrarily and capriciously 
interpreted the CSA.
203
  The First Circuit concluded that Congress had provided the 
DEA with sole power to determine the relative potential for abuse of a substance, so 
long as it provided substantial evidence in that regard.
204
  Finding that Congress 
delegated that authority, and that the conclusion was based on substantial evidence, 
the Court refrained from finding the DEA ruling invalid on “arbitrary and capricious” 
grounds.
205
  The Court stated the following:   
While we acknowledge that the Administrator's final rule is silent with 
respect to the legal standard required for a finding of “high” potential for 
abuse, we do not find the Administrator's action to be arbitrary and 
capricious. The fourth standard contained in the segment of the Committee 
Report quoted above makes it quite clear that the Administrator can 
permissibly reach a conclusion regarding a substance's level of potential for 
abuse by comparing the substance to drugs already scheduled under the 
                                                          
 196 Grinspoon, 828 F.2d at 883. 
 197 Id. 
 198 Id. 
 199 Id. 
 200 Id. 
 201 Id. at 884. 
 202 Id. at 892.  
 203 Id. 
 204 Id.  
 205 Id.  
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CSA. Here the Administrator has done just that, offering several findings 
concerning the evidence of close structural and pharmacological similarity 
between MDMA and other substances, such as MDA,12 which already 
*894 have been found to have a high potential for abuse and have been 
placed in Schedule I or II.
206
  
 Additionally, the Court acknowledged the legislative history of the Controlled 
Substances Act.
207
  The House Committee Report provided that the Administrator can 
find a potential for abuse if the following apply:  
(1) There is evidence that individuals are taking the drug or drugs 
containing such a substance in amounts sufficient to create a hazard to their 
health or to the safety of other individuals or of the community; or 
 
(2) There is significant diversion of the drug or drugs containing such a 
substance from legitimate drug channels; or 
 
(3) Individuals are taking the drug or drugs containing such a substance on 
their own initiative rather than on the basis of medical advice from a 
practitioner licensed by law to administer such drugs in the course of his 
professional practice; or 
 
(4) The drug or drugs containing such a substance are new drugs so related 
in their action to a drug or drugs already listed as having a potential for 
abuse to make it likely that the drug will have the same potentiality for 
abuse as such drugs, thus making it reasonable to assume that there may be 
significant diversions from legitimate channels, significant use contrary to 
or without medical advice, or that it has a substantial capability of creating 
hazards to the health of the user or to the safety of the community.
208
 
 
Here, the court found that the director adhered to the Congressional intent of the 
CSA as it pertains to a high potential for abuse.
209
  The court stated that the 
Administrator “offered several findings concerning the evidence of a close structural 
pharmacological similarity between MDMA and MDA, which have already been 
found to have a high potential for abuse and have been placed in Schedule I.
210
  
Further, the Administrator provided “animal studies, human behavioral studies, and a 
survey of MDMA users which suggest[ed] that MDMA is related in its effects to 
Schedule I substances such as LSD, cocaine, mescaline, and MDA.”211  The court 
concluded that the Administrators approach in analyzing the potential for abuse 
                                                          
 206 51 Fed.Reg. 36,555–57 (1986). 
 207 Grinspoon 828 F.2d, 983at 885. 
 208 Id.   
 209 Id.   
 210 Id. 
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conformed to the intent of Congress, and thus did not render the decision arbitrary and 
capricious under the Chevron framework.
212
   
Nonetheless, as demonstrated many studies cited in this article and Dr. 
Grinspoon’s arguments before the First Circuit, the question remains as to “whether 
the evidence collected by the administrator is sufficient to justify his conclusion that 
MDMA has a high potential for abuse.”213 
B. The First Circuit Incorrectly Concludes that the Director’s Conclusions were 
Sufficient under the “Substantial Evidence” Standard 
There is no doubt that the CSA’s legislative history demonstrates Congressional 
intent in delegating the “high potential for abuse” determination to the 
administrator.
214
  That being said, the crucial analysis is whether that conclusion can 
withstand the notoriously low “substantial evidence” standard.  In Am. Textile Mfrs. 
Inst. v. Donovan, the Supreme Court held that substantial evidence is that which “such 
relevant evidence as a reasonable mind might accept as adequate to support a 
conclusion”215  “[E]ven if reasonable minds could also go the other way, we must 
uphold the [agency] if its ultimate finding is supported by substantial evidence in the 
record as a whole."
216
 
In his original 1986 ruling, Director Lawn cited various scientific studies to 
support his conclusion that MDMA had a high potential for abuse.
217
  At that time, 
Dr. Grinspoon a professor of psychiatry at Harvard University and a medical 
researcher, presented his and other professionals studies on the efficacy of MDMA as 
                                                          
 212 Id.  
 213 Id.  
 214 Id.  “From this, the Administrator draws the proposition that “Congress clearly intended 
that the ‘safety and efficacy’ of narcotic and dangerous drugs (e.g., whether such drugs are 
acceptable for medical use and safe for such use) be determined by [HHS] under the [FDCA].” 
Respondent's Brief at 17–18 (emphasis deleted). The Administrator's conclusion is 
objectionable, however, because his parenthetical comment—equating a finding of “safety and 
efficacy” by the FDA with a finding of “accepted medical use” and “accepted safety for use ... 
under medical supervision”—is totally unsupported by the quoted passage from the House 
Committee Report. Nowhere does Congress equate “safety and efficacy” under the FDCA with 
the second and third Schedule I criteria contained in section 812(b)(1). This, indeed, is the point 
at issue in this litigation, and we are loath to accept such a disingenuous argument.”  Id.   
 215 Am. Textile Mfrs. Inst. v. Donovan, 452 U.S. 490, 522 (U.S. 1981). 
 216 Id. (citing NLRB v. J.K. electronics, Inc. v. Donovan, 452 U.S. 490 (1981). 
 217  “(1) MDMA is the N-methyl analogue of MDA and retains the psychomimetic properties 
of MDA; (2) MDMA produces pharmacological effects in common with both central nervous 
system ("CNS") stimulants like amphetamine and hallucinogens like MDA in animals; (3) 
MDMA and MDA produce the same spectrum of pharmacological effects in mice, dogs, and 
monkeys when observed during toxicity studies; (4) MDMA, like MDA, amphetamine, and 
methamphetamine, produces neurotoxic effects when administered to animals; (5) MDMA and 
MDA may both produce the same neurotoxic effects to serotonergic nerves in humans; (6) in 
drug discrimination tests, rats trained to recognize amphetamine also recognized MDA and 
MDMA, and rats trained to recognize MDA also recognized MDMA; (7) based on recent tests 
involving human subjects, MDMA can be described as maintaining the same potency as MDA, 
but exhibiting subtle differences in the qualitative nature of the intoxication.”  Grinspoon, supra 
note 207at 895. 
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an adjunct to therapy.
218
  Nonetheless, the Court upheld the agency determination that 
MDMA had a high potential for abuse, noting that an “appellate court must not 
second-guess the particular way the agency chooses to weigh the conflicting evidence 
or resolve the dispute.”219 
In the event that an agency points to “scientifically respectable evidence” that a 
petitioner can “continually dispute with rival, and…equally respectable evidence,” the 
court will not question the means by which the agency chooses resolve the dispute.
220
  
Under this framework, substantial evidence must be “scientifically respectable” and, 
when a conflict between evidence exists, an agency must resolve that dispute.
221
 
Director Lawn relied upon evidence in the record that is no longer “scientifically 
respectable” as it pertains to our current understanding of the neurotherapuetic effects 
of MDMA, especially when viewing within the context of post-traumatic stress 
disorder.
222
  For example, current MDMA research concludes that MDMA lacks the 
addictive qualities present in other Schedule I substances like cocaine and heroin.
223
   
Further, current research shows that MDMA does not cause lead to neurotoxicity 
when taken recreationally.  One of the largest studies on MDMA, researchers from the 
UK concluded that “MDMA use may not result in long-term damage to serotonin 
neurons when used recreationally in humans.”224  Nor is such a finding subject to 
conflict, as the studies cited by the Director measure the effect of MDMA when issued 
at a threshold level.
225
   This neurotoxic effect is substantially less than those 
frequently identified in heroin and cocaine use.
226
  MDMA only produces neurotoxic 
effects when distributed at its threshold level in nonhuman animals; human studies 
                                                          
 218 Id. 
 219 Id. 
 220 Asarco, Inc. v. OSHA, 746 F.2d 483 (9th Cir. 1984).  Where the agency presents 
scientifically respectable evidence which the petitioner can continually dispute with rival, and 
we will assume, equally respectable evidence, the court must not second-guess the particular 
way the agency chooses to weigh the conflicting evidence or resolve the dispute.  Id. (emphasis 
added).  
 221 Id.   
 222 See generally Multidisciplinary Association for Psychedelic Studies, 
http://www.maps.org/research/mdma . 
 223 Johansen & Krebs, Psychedelics not linked to mental health problems or suicidal 
behavior: a population study, J. of Psychopharmacology. 
 224 Selvaraj, et. al., Brain serotonin transporter binding in former users of MDMA, 194 Brit. 
J. of Psychiatry 355-359 (2009).  
 225 See 53 FR 5156-01; see also Selvaraj supra note 224. 
 226 Oliveira¸et. al., Neurotoxicity of heroin-cocaine combinations in rat cortical neurons, 276 
J. of Toxicology 11 (2010).  “The data show that drug combinations potentiate cortical 
neurotoxicity and that the mode of co-exposure changes cellular death pathways activated by 
the drugs, strongly suggesting that chemical interactions occurring in Her:Coc, such as adduct 
formation, shift cell death mechanisms towards necrosis. Since impairment of the prefrontal 
cortex is involved in the loss of impulse control observed in drug addicts, the data presented 
here may contribute to explain the increase in treatment failure observed in speedball abusers.”  
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have not produced any of evidence of neurotoxic damage or neurodegeneration 
following therapeutic use.
227
 
When looking at the Director Lawn’s rationale in 1986, it becomes apparent that 
the medical purposes for which Dr. Grinspoon argued were not met with substantially 
conflicting evidence, as the only studies present in the Committee Report contain 
studies administering MDMA to animals at threshold, or maximum LD/50 levels, and 
not over an extended period of time.  Furthermore, a host of scientific data exists 
differentiating MDMA’s potential from abuse from other Schedule I substances, with 
some studies concluding that MDMA has no potential for abuse whatsoever.  
Regardless of a small potential for abuse, it is not high, as required by the CSA, nor is 
it at all comparable to substances with which it currently shares Schedule I status.    
Nonetheless, DEA scheduling updates and completed lists are reviewed and restated 
bi-annually.
228
  With the growing body of data demonstrating MDMA’s positive 
effect on PTSD victims, coupled with the ineffective treatments currently available to 
veterans suffering with the disease, there is substantial evidence to support a second 
challenge to the rule, and a reversal or reconsideration of Director Lawn’s 1986 
classification.   
 
V.  MDMA IN SCHEDULE III 
A.  Meeting the Schedule III Criteria 
Schedule III substances are those that the DEA concludes have an accepted 
medical use in the United States, a lower potential for abuse than those substances in 
Schedule I and II, and low physical dependence or high psychological dependence.
229
  
Doctors may prescribe Schedule III substances to patients, but the sale or ingestion 
without a prescription is illegal.
230
  Based on the analysis above, MDMA is most 
reasonably categorized as a Schedule III substance under the Controlled Substances 
Act.
231
 
                                                          
 227 Id.  
 228 Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination 
Products from Schedule III to Schedule II, 21 C.F.R. 1308, available at 
https://www.federalregister.gov/articles/2014/08/22/2014-19922/schedules-of-controlled-
substances-rescheduling-of-hydrocodone-combination-products-from-
schedulehttps://www.federalregister.gov/articles/2014/08/22/2014-19922/schedules-of-
controlled-substances-rescheduling-of-hydrocodone-combination-products-from-schedule .  
 229 21 U.S.C. §829 (2016). 
(b) Schedule III and IV substances 
 
Except when dispensed directly by a practitioner, other than a pharmacist, to an ultimate 
user, no controlled substance in schedule III or IV, which is a prescription drug as 
determined under the Federal Food, Drug, and Cosmetic Act, may be dispensed without 
a written or oral prescription in conformity with section 503(b) of that Act. Such 
prescriptions may not be filled or refilled more than six months after the date thereof or 
be refilled more than five times after the date of the prescription unless renewed by the 
practitioner. 21 U.S.C. §829 (2016).   
 230 21 U.S.C §812 (2016). 
 231 See Marsha Rosenbaum & Rick Doblin, A Short History of MDMA Use, (1991). 
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Under § 812 of the CSA, the “known facts as to MDMA must be compared with 
the known facts as to human abuse of other substances.”232  Consider cocaine, for 
example. Cocaine causes a far greater amount of problems in the United States as a 
result of its addictive qualities.
233
  Cocaine produces a high tolerance in users, 
produces pleasurable sensations in the brain that incite repetitive use and inevitable 
addiction, and is used in a much more consistent way than MDMA.
234
  Regardless of 
these marked differences in abuse prevalence, MDMA and cocaine share Schedule I 
classification due to a lack of accepted medical use and high potential for abuse.
235
 
Aside from MDMA’s social and habitual distinction from cocaine, researchers 
have examined MDMA’s potential for abuse in animal studies on rhesus monkeys.236  
Medical researchers have tested many Schedule I, II, and III substances on rhesus 
monkeys to determine a potential for abuse by looking at primate rates of self-
administration.
237
 These tests measure the rate at which monkeys, generally rhesus 
monkeys, ingest a particular substance after an initial dosage.
238
 Studies of MDMA 
indicate that rhesus monkeys self-administer the drug less than other Schedule I 
substances, such as cocaine or heroin.
239
 
Only a small amount of studies have examined MDMA dependence in humans.
240
  
Those studies indicate that ecstasy produces withdrawal symptoms in heavy users.
241
  
Nonetheless, “craving for ecstasy was low overall,” and social factors, not 
physiological responses, incited urges to take MDMA.
242
  Thus, “physiological basis 
of an ecstasy dependence syndrome might be relatively weaker in comparison to drugs 
with clear and marked dependence potential” such as cocaine or other Schedule I 
opioids.
243
 
Scientists at the University of Toronto uncovered the acute and long-term effects 
of MDMA in average users.
244
  Acute effects ranged from renewed energy, a sense of 
fulfillment, increased sexual arousal, and an overwhelming sense of euphoria, to 
                                                          
 232 D.E.A., In the Matter of MDMA Scheduling, no 84-48 (1986). 
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 234 Id.  
 235 21 U.S.C. §812 (2016). 
 236 Zarembo supra note 91. 
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 239 See Louisa, Degenhardt ET AL., Is Ecstasy a Drug of Dependence? 107 DRUG AND 
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increases in body temperature, heart rate, and a sense of a mental and physical 
“crash”.245 
Studies of long-term MDMA users shows a prevalence of “serotonin 
neurotoxicity.”246  The substantial release of serotonin produced by MDMA intake 
causes damage to serotonin metabolites in the cerebrospinal fluid.
247
  A long-term 
MDMA user releases less serotonin during “neuronal,” or regular activity in brain 
activity, has “abnormally low levels of serotonin,” a smaller amount of serotonin 
transporter molecules, and altered pattern of blood flow to the brain.”248 
These physical and psychological effects, though significant, do not comport to 
the physical and psychological effects of other Schedule I substances.
249
  For example, 
MDA (3,4-Methylenedioxyamphetamine), a structural relative of MDMA, produces 
cognitive impairment at low dosage levels and causes hallucinations and 
disorientation.
250
 Physical effects of drugs such as methamphetamine, heroin, and 
cocaine far outweigh those produced by MDMA.
251
  These drugs are far more 
addictive and cause irreparable harm to the human nervous system.
252
 
Several Schedule III substances share similar qualities with MDMA in the context 
of physical dependence.  For example, Benzphetamine is an amphetamine that 
metabolizes into a methamphetamine upon digestion.
253
   Benzphetamine suppresses 
appetite in order to reduce caloric intake in obese patients.
254
 
Due to its low potential for abuse and low physical dependence, MDMA 
reasonably conforms to the substance characteristics set out in Schedule III.  MDMA 
possesses a significantly smaller potential for abuse in primate and human subjects 
than other Schedule I substances.
255
 Further, it does not cause a strong physical or 
psychological dependence in humans.
256
  The physiological effects are relatively 
minimum, and the fluctuation of serotonin levels emulate many Schedule III 
substances.  Accordingly, research today urges Schedule III classification.  
                                                          
 245 Id. 
 246 See George Ricaurte ET AL., (±) 3, 4-Methylenedioxymethamphetamine (‘Ecstasy’)-
induced Serotonin Neurotoxicity: Studies in Animals, 42 NEUROPSYCHOBIOLOGY 5-10 (2000). 
 247 Id.   
 248 Id.   
 249 See generally JULIE HOLLAND, A COMPREHENSIVE LOOK AT THE RISKS AND BENEFITS OF 
MDMA (Inner Traditions/Bear & Co. ed. 2001).  
 250 See Shuglin supra, 38. 
 251 See Reneman supra, 160. 
 252 Id. 
 253 F. Musshoff,  Illegal or Legitimate Use? Precursor Compounds to Amphetamine and 
Methamphetamine, 32 DRUG METABOLISM REVIEWS 15-44 (2000). 
 254 When abused, however, Benzphetamine may cause severe hallucinations.   Similarly, 
Clortermine and Phendimetrazine are appetite suppressors that act on serotonin levels in the 
brain.  Methamphetamine comprises the structure of both of these substances, as well as 
MDMA.   See Id. 
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B.  Impact of Schedule III Classification of MDMA Treatment in Veterans Suffering 
with PTSD 
Reclassifying MDMA as a Schedule III substance would provide veterans with an 
opportunity to experience the benefits of MDMA-assisted psychotherapy.
257
  Such a 
notion is slowly becoming reality, as the Multidisciplinary Association for 
Psychedelic Substances recently completed a Phase 2 Pilot Study of MDMA in 
therapy settings.
258
  The end goal of this study is to acquire approval of MDMA as a 
prescription substance by 2021.
259
  This goal is unattainable in the United States so 
long as MDMA remains classified as a substance lacking any accepted medical use.
260
  
In the United States, the FDA has only approved of two pharmacological 
treatments for victims of PTSD: Zoloft and Paxil.
261
  Zoloft and Paxil act to increase 
the amount of serotonin in the brain, utilizing the exact same mechanism as 
MDMA.
262
  MDMA affects serotonin levels “acutely for 4-8 hours,” whereas Zoloft 
and Paxil chronically affect serotonin levels and must be taken daily.
263
  Thus, 
medication not only becomes more burdensome on the patient but more financially 
impactful on tight-budgeted organizations like the VA.
264
 
If MDMA becomes a Schedule III narcotic in the near future, a plethora of 
“bureaucratic delays” could be avoided.  Research on MDMA’s effect on PTSD would 
not be restricted by the necessity of FDA approval; mandatory registration with the 
DEA would no longer hinder the once swift and fluid process of research; medical 
researchers would not be deterred from furthering their studies because of stringent 
DEA reporting guidelines; an inappropriate and unfounded national stigma could be 
corrected, and the long road to addressing PTSD could shorten significantly. 
 
VI. CONCLUSION 
The justifications for rescheduling MDMA as a Schedule III substance are 
plentiful, and as the decade—and the war against posttraumatic stress—continues, 
those reasons will continue to present themselves in an irrefutable light.  The 
understanding of MDMA’s medically accepted use has grown substantially since its 
Schedule I classification in 1986.
265
  Though the stigma against MDMA exists en 
masse, its efficacy of a treatment in the limited context of posttraumatic stress disorder 
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is piercing societal perception.  It is this treatment—an alternative approach to halting 
an ever-expanding disorder—that solely justifies a DEA interpretation of the 
“medically accepted use” standard.  To give MDMA Schedule III status would not 
interrupt the Congressional purpose behind the CSA, and would funnel treatment to a 
much-needed group of afflicted individuals.    
More prevalent than MDMA’s effect on posttraumatic stress disorder is its power 
over addiction. Its importance to returning veterans becomes ever the more crucial, as 
addiction is one of the strongest, most consistent, and must exacerbating of the 
symptoms of PTSD.  Again, when viewing MDMA within the context of surrounding 
Schedule I narcotics, there is a vast discrepancy in rates of addiction.
266
  Further, the 
psychedelic—scientifically referred to as hallucinogenic—substances are in that rare 
class of Schedule I drugs that have shown positive results insofar as they alleviate 
addiction.  Thus, a sort of tragic irony exists here, whereby substances deemed as 
having a “high potential for abuse” in fact function to curb the abuse of other, more 
dangerous Schedule I narcotics. 
Physiologically, MDMA acts as a stimulant, increasing heart rate and blood 
pressure.
267
 Accompanying these physical symptoms is a subjective, but uniform 
sense of euphoria, love, and compassion, effects that countless of veterans have 
reported following MDMA-assisted therapy.
268
  This is a fundamental change in 
perspective that has the opportunity to be incited without forcing veterans to seek 
illegal means to that end.
269
   The efficacy of MDMA-assisted therapy in treating 
PTSD has brought MDMA into the international healthcare discussion.  The 
justifications for keeping it out of the hands of healthcare professionals and patients 
far outweigh the physiological and psychological effects of the substance on humans. 
Thus, access to MDMA must be provided to veterans if PTSD is to be meaningfully 
treated in the near future. 
In the last decade, scientific progress has elucidated the power of a stigmatized and 
illegalized substance with regard to its effective use in therapy.  It is important to note 
that the Controlled Substances Act is open for rescheduling hearings on an annual 
basis.
270
  As a result, the DEA will be presented with the opportunity to conform its 
legislation to the scientific understand regarding MDMA and its use in psychotherapy, 
and will have the opportunity to do so without frustrating congressional purpose.  A 
rescheduling of the substance to Schedule III, as opposed to Schedule I, would provide 
physicians with the ability to administer MDMA in dispersed therapy sessions over a 
wide range of time, a technique with proven benefits unseen in the current 
antidepressant atmosphere.  Making this change will allow outdated drug legislation 
to catch up with scientific progress, and in doing so, make a meaningful and necessary 
step toward addressing PTSD in American veterans. 
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